You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHaloperidol
Accession NumberDB00502  (APRD00538)
TypeSmall Molecule
GroupsApproved
DescriptionA phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)
Structure
Thumb
Synonyms
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
Haldol
Haloperidolum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HaldolInjection5 mg/mLIntramuscularJanssen Pharmaceuticals, Inc.1971-05-18Not applicableUs
Haldol DecanoateInjection50 mg/mLIntramuscularJanssen Pharmaceuticals, Inc.1986-01-14Not applicableUs
Haldol DecanoateInjection100 mg/mLIntramuscularJanssen Pharmaceuticals, Inc.1986-01-14Not applicableUs
Haldol Injection 5mg/mlLiquid5 mgIntramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1966-12-312006-08-04Canada
Haldol LA Inj 100mg/mlLiquid100 mgIntramuscularJanssen Inc1983-12-312006-08-04Canada
Haldol LA Inj 50mg/mlLiquid50 mgIntramuscularJanssen Inc1983-12-312006-01-23Canada
HaloperidolInjection5 mg/mLIntramuscularPatriot Pharmaceuticals LLC2011-06-29Not applicableUs
HaloperidolInjection5 mg/1IntramuscularREMEDYREPACK INC.2013-04-10Not applicableUs
HaloperidolInjection5 mg/mLIntramuscularTYA Pharmaceuticals2011-06-17Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularPatriot Pharmaceuticals LLC2011-06-17Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularPatriot Pharmaceuticals LLC2011-06-17Not applicableUs
Haloperidol Decanoate Inj. Liq Im 100mg/mlLiquid100 mgIntramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada
Haloperidol Decanoate Inj. Liq Im 50mg/mlLiquid50 mgIntramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada
Haloperidol Decanoate InjectionSolution50 mgIntramuscularMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Haloperidol Decanoate InjectionLiquid50 mgIntramuscularHospira Healthcare CorporationNot applicableNot applicableCanada
Haloperidol Decanoate InjectionSolution100 mgIntramuscularMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Haloperidol Decanoate InjectionLiquid100 mgIntramuscularHospira Healthcare CorporationNot applicableNot applicableCanada
Haloperidol Inj 5mg/ml USPLiquid5 mgIntramuscularSandoz Canada Incorporated1989-12-31Not applicableCanada
Haloperidol InjectionSolution5 mgIntramuscularOmega Laboratories Ltd2011-09-19Not applicableCanada
Haloperidol Injection, USPSolution5 mgIntramuscularFresenius Kabi Canada Ltd2014-10-20Not applicableCanada
Haloperidol LALiquid50 mgIntramuscularSandoz Canada Incorporated1994-12-31Not applicableCanada
Haloperidol LALiquid100 mgIntramuscularSandoz Canada Incorporated1994-12-31Not applicableCanada
Haloperidol Long ActingLiquid100 mgIntramuscularNovopharm Limited2001-08-022005-08-10Canada
Haloperidol Long ActingLiquid50 mgIntramuscularNovopharm Limited2001-08-022005-08-10Canada
Haloperidol Tab 0.5mgTablet.5 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Haloperidol Tab 1mgTablet1 mgOralPro Doc Limitee1983-12-312010-07-13Canada
Haloperidol Tab 2mgTablet2 mgOralPro Doc Limitee1988-12-312010-07-13Canada
Haloperidol Tab 5mgTablet5 mgOralPro Doc Limitee1988-12-312010-07-13Canada
Haloperidol-10 Tab 10mgTablet10 mgOralPro Doc Limitee1988-12-312010-07-13Canada
Haloperidol-LA OmegaLiquid50 mgIntramuscularOmega Laboratories Ltd1999-06-30Not applicableCanada
Haloperidol-LA OmegaLiquid100 mgIntramuscularOmega Laboratories Ltd1999-05-28Not applicableCanada
Novo-peridol Oral Soln 2mg/mlSolution2 mgOralNovopharm Limited1987-12-312005-08-10Canada
Nu-haloperidolTablet1 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidolTablet2 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidolTablet5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidolTablet0.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidolTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-haloperidol Soln 2mg/mlSolution2 mgOralPharmascience Inc1988-12-31Not applicableCanada
PMS-haloperidol-LALiquid50 mgIntramuscularPharmascience Inc1997-09-24Not applicableCanada
PMS-haloperidol-LALiquid100 mgIntramuscularPharmascience Inc1997-08-17Not applicableCanada
Ratio-haloperidol 2mg/mlSolution2 mgOralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada
Ratio-haloperidol Tab 0.5mgTablet.5 mgOralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada
Ratio-haloperidol Tab 10mgTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited1987-12-312006-08-04Canada
Ratio-haloperidol Tab 1mgTablet1 mgOralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada
Ratio-haloperidol Tab 2mgTablet2 mgOralRatiopharm Inc Division Of Teva Canada Limited1987-12-312006-08-04Canada
Ratio-haloperidol Tab 5mgTablet5 mgOralRatiopharm Inc Division Of Teva Canada Limited1985-12-312006-08-04Canada
Rho-haloperidol Decanoate Inj.-im 100mg/mlSolution100 mgIntramuscularRhodiapharm Inc1997-05-072005-08-01Canada
Rho-haloperidol Decanoate Inj.-im 50mg/mlSolution50 mgIntramuscularRhodiapharm Inc1997-05-072005-08-01Canada
Teva-haloperidolTablet0.5 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Teva-haloperidolTablet20 mgOralTeva Canada Limited1988-12-31Not applicableCanada
Teva-haloperidolTablet1 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Teva-haloperidolTablet2 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Teva-haloperidolTablet10 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Teva-haloperidolTablet5 mgOralTeva Canada Limited1984-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Haloperidol Liq 2mg/mlLiquid2 mgOralApotex Inc1983-12-31Not applicableCanada
Apo Haloperidol Tab 0.5mgTablet.5 mgOralApotex Inc1980-12-31Not applicableCanada
Apo Haloperidol Tab 1mgTablet1 mgOralApotex Inc1980-12-31Not applicableCanada
Apo-haloperidol LA InjectableLiquid100 mgIntramuscularApotex Inc2000-06-302013-08-02Canada
Apo-haloperidol LA InjectableLiquid50 mgIntramuscularApotex Inc2000-06-302013-08-02Canada
Apo-haloperidol Tab 10mgTablet10 mgOralApotex Inc1987-12-31Not applicableCanada
Apo-haloperidol Tab 2mgTablet2 mgOralApotex Inc1987-12-31Not applicableCanada
Apo-haloperidol Tab 5mgTablet5 mgOralApotex Inc1987-12-31Not applicableCanada
HaloperidolInjection, solution5 mg/mLIntramuscularSagent Pharmaceuticals2011-10-24Not applicableUs
HaloperidolTablet5 mg/1OralCardinal Health2004-02-15Not applicableUs
HaloperidolTablet5 mg/1OralCadila Healthcare Limited2008-01-03Not applicableUs
HaloperidolTablet5 mg/1OralMc Kesson Contract Packaging2013-04-10Not applicableUs
HaloperidolTablet2 mg/1OralREMEDYREPACK INC.2008-04-29Not applicableUs
HaloperidolSolution2 mg/mLOralSilarx Pharmaceuticals, Inc2009-09-08Not applicableUs
HaloperidolTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-03-11Not applicableUs
HaloperidolTablet20 mg/1OralSandoz Inc1988-03-11Not applicableUs
HaloperidolTablet20 mg/1OralREMEDYREPACK INC.2013-02-19Not applicableUs
HaloperidolTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
HaloperidolTablet2 mg/1OralClinical Solutions Wholesale1986-11-17Not applicableUs
HaloperidolTablet10 mg/1OralMylan Pharmaceuticals Inc.2009-07-17Not applicableUs
HaloperidolInjection, solution5 mg/mLIntramuscularPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs
HaloperidolTablet5 mg/1OralCardinal Health1986-06-10Not applicableUs
HaloperidolTablet5 mg/1OralCardinal Health1986-11-17Not applicableUs
HaloperidolTablet5 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
HaloperidolTablet1 mg/1OralSandoz Inc1986-11-17Not applicableUs
HaloperidolTablet.5 mg/1OralMylan Institutional Inc.2004-02-01Not applicableUs
HaloperidolTablet2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HaloperidolInjection5 mg/mLIntramuscularGeneral Injectables and Vaccines, Inc2014-09-29Not applicableUs
HaloperidolInjection5 mg/mLIntramuscularCardinal Health2001-06-19Not applicableUs
HaloperidolTablet2 mg/1OralTYA Pharmaceuticals1986-06-10Not applicableUs
HaloperidolTablet5 mg/1OralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs
HaloperidolTablet5 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
HaloperidolTablet10 mg/1OralREMEDYREPACK INC.2016-11-30Not applicableUs
HaloperidolTablet1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
HaloperidolTablet10 mg/1OralMajor Pharmaceuticals2015-03-25Not applicableUs
HaloperidolInjection5 mg/mLIntramuscularTeva Parenteral Medicines, Inc.2002-03-012016-10-13Us
HaloperidolInjection, solution5 mg/mLIntramuscularSagent Pharmaceuticals2011-10-24Not applicableUs
HaloperidolTablet1 mg/1OralCardinal Health2012-09-05Not applicableUs
HaloperidolTablet10 mg/1OralCadila Healthcare Limited2008-01-03Not applicableUs
HaloperidolInjection, solution5 mg/mLIntramuscularREMEDYREPACK INC.2013-06-132016-10-28Us
HaloperidolTablet5 mg/1OralREMEDYREPACK INC.2016-11-14Not applicableUs
HaloperidolTablet20 mg/1OralMylan Pharmaceuticals Inc.2009-07-17Not applicableUs
HaloperidolSolution, concentrate2 mg/mLOralPharmaceutical Associates, Inc.2009-11-10Not applicableUs
HaloperidolTablet1 mg/1OralMajor Pharmaceuticals2009-02-19Not applicableUs
HaloperidolTablet2 mg/1OralREMEDYREPACK INC.2013-07-01Not applicableUs
HaloperidolTablet1 mg/1OralPhysicians Total Care, Inc.1995-07-26Not applicableUs
HaloperidolTablet10 mg/1OralAmerican Health Packaging2008-03-04Not applicableUs
HaloperidolTablet5 mg/1OralAmerican Health Packaging2016-02-08Not applicableUs
HaloperidolTablet5 mg/1OralClinical Solutions Wholesale1986-11-17Not applicableUs
HaloperidolTablet1 mg/1OralMylan Institutional Inc.2004-02-01Not applicableUs
HaloperidolTablet2 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HaloperidolTablet2 mg/1OralCardinal Health1986-11-17Not applicableUs
HaloperidolTablet2 mg/1OralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
HaloperidolTablet2 mg/1OralSandoz Inc1986-11-17Not applicableUs
HaloperidolTablet5 mg/1OralRebel Distributors Corp1986-11-17Not applicableUs
HaloperidolInjection5 mg/mLIntramuscularCardinal Health2001-08-29Not applicableUs
HaloperidolTablet5 mg/1OralTYA Pharmaceuticals1986-06-10Not applicableUs
HaloperidolTablet10 mg/1OralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs
HaloperidolTablet5 mg/1OralDIRECT RX2014-01-01Not applicableUs
HaloperidolInjection, solution5 mg/mLOralREMEDYREPACK INC.2016-12-02Not applicableUs
HaloperidolTablet2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
HaloperidolTablet5 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
HaloperidolInjection5 mg/mLIntramuscularTeva Parenteral Medicines, Inc.2002-03-012016-10-13Us
HaloperidolTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.1986-06-10Not applicableUs
HaloperidolTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HaloperidolTablet2 mg/1OralCardinal Health2012-09-05Not applicableUs
HaloperidolTablet20 mg/1OralCadila Healthcare Limited2008-01-03Not applicableUs
HaloperidolTablet.5 mg/1OralCardinal Health1986-11-17Not applicableUs
HaloperidolSolution, concentrate2 mg/mLOralTeva Pharmaceuticals USA Inc1988-12-01Not applicableUs
HaloperidolTablet10 mg/1OralClinical Solutions Wholesale1988-03-11Not applicableUs
HaloperidolTablet.5 mg/1OralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
HaloperidolSolution2 mg/mLOralQualitest Pharmaceuticals1993-09-282016-11-18Us
HaloperidolTablet2 mg/1OralMajor Pharmaceuticals2009-02-19Not applicableUs
HaloperidolTablet.5 mg/1OralREMEDYREPACK INC.2014-05-13Not applicableUs
HaloperidolTablet5 mg/1OralPhysicians Total Care, Inc.1996-10-24Not applicableUs
HaloperidolInjection, solution5 mg/mLIntramuscularFresenius Kabi USA, LLC2000-10-20Not applicableUs
HaloperidolTablet20 mg/1OralAmerican Health Packaging2008-04-02Not applicableUs
HaloperidolTablet2 mg/1OralMylan Institutional Inc.2004-02-15Not applicableUs
HaloperidolTablet2 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
HaloperidolInjection, solution5 mg/mLIntramuscularCardinal Health2010-12-15Not applicableUs
HaloperidolTablet.5 mg/1OralClinical Solutions Wholesale1986-11-17Not applicableUs
HaloperidolTablet1 mg/1OralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
HaloperidolTablet5 mg/1OralSandoz Inc1986-11-17Not applicableUs
HaloperidolTablet5 mg/1OralREMEDYREPACK INC.2010-12-212016-10-25Us
HaloperidolInjection, solution5 mg/mLIntramuscularCardinal Health2011-05-10Not applicableUs
HaloperidolTablet20 mg/1OralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs
HaloperidolTablet10 mg/1OralREMEDYREPACK INC.2010-08-12Not applicableUs
HaloperidolTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
HaloperidolTablet1 mg/1OralCardinal Health1986-11-17Not applicableUs
HaloperidolTablet1 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
HaloperidolTablet.5 mg/1OralSandoz Inc1986-11-17Not applicableUs
HaloperidolTablet10 mg/1OralMylan Institutional Inc.2009-08-03Not applicableUs
HaloperidolTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HaloperidolTablet.5 mg/1OralCardinal Health2012-09-05Not applicableUs
HaloperidolTablet5 mg/1OralContract Pharmacy Services Pa2010-07-28Not applicableUs
HaloperidolTablet10 mg/1OralTYA Pharmaceuticals2008-01-03Not applicableUs
HaloperidolTablet1 mg/1OralDispensing Solutions, Inc.1986-11-17Not applicableUs
HaloperidolTablet.5 mg/1OralREMEDYREPACK INC.2007-04-09Not applicableUs
HaloperidolTablet2 mg/1OralREMEDYREPACK INC.2010-10-27Not applicableUs
HaloperidolTablet.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
HaloperidolTablet5 mg/1OralMajor Pharmaceuticals2009-02-19Not applicableUs
HaloperidolTablet.5 mg/1OralPhysicians Total Care, Inc.1999-04-29Not applicableUs
HaloperidolTablet5 mg/1OralMylan Institutional Inc.2004-02-15Not applicableUs
HaloperidolTablet1 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
HaloperidolTablet1 mg/1OralLake Erie Medical DBA Quality Care Products LLC1986-11-17Not applicableUs
HaloperidolTablet1 mg/1OralClinical Solutions Wholesale1986-11-17Not applicableUs
HaloperidolTablet5 mg/1OralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
HaloperidolTablet10 mg/1OralSandoz Inc1988-03-11Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularFresenius Kabi USA, LLC2000-02-16Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularTeva Parenteral Medicines, Inc.1999-07-01Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularFresenius Kabi USA, LLC2000-07-12Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularTeva Parenteral Medicines, Inc.1999-06-04Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularTYA Pharmaceuticals2000-07-12Not applicableUs
Haloperidol DecanoateInjection100 mg/mLIntramuscularTeva Parenteral Medicines, Inc.1999-07-01Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularTeva Parenteral Medicines, Inc.1999-06-04Not applicableUs
Haloperidol DecanoateInjection50 mg/mLIntramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol LactateInjection, solution5 mg/mLIntramuscularMylan Institutional LLC2011-05-10Not applicableUs
Haloperidol LactateInjection, solution5 mg/mLIntramuscularCardinal Health2011-05-10Not applicableUs
Haloperidol LactateInjection5 mg/mLIntramuscularGENERAL INJECTABLES AND VACCINES, INC.2015-10-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AloperidinJanssen-Cilag
BioperidoloFirma
BrotoponPfizer
DozicRosemont
DuraperidolNot Available
Einalon SNot Available
EukystolMerckle
HalostenShionogi Seiyaku
KeselanSumitomo
LintonTanabe Mitsubishi Pharma
Peluceslsei
SerenacePfizer
SigaperidolSiegfried
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Haloperidol decanoate
74050-97-8
Thumb
  • InChI Key: GUTXTARXLVFHDK-UHFFFAOYSA-N
  • Monoisotopic Mass: 529.2759
  • Average Mass: 530.12
DBSALT001195
Haloperidol lactate
53515-91-6
Thumb
  • InChI Key: BVUSNQJCSYDJJG-UHFFFAOYSA-N
  • Monoisotopic Mass: 465.1718289
  • Average Mass: 465.95
DBSALT001232
Categories
UNIIJ6292F8L3D
CAS number52-86-8
WeightAverage: 375.864
Monoisotopic: 375.140134897
Chemical FormulaC21H23ClFNO2
InChI KeyLNEPOXFFQSENCJ-UHFFFAOYSA-N
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Pharmacology
IndicationFor the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.
Structured Indications
PharmacodynamicsHaloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Mechanism of actionThe precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
Glutamate receptor ionotropic, NMDA 2BProteinunknown
antagonist
HumanQ13224 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
5-hydroxytryptamine receptor 2AProteinunknown
other/unknown
HumanP28223 details
D(3) dopamine receptorProteinunknown
inverse agonist
HumanP35462 details
Related Articles
AbsorptionOral-60%
Volume of distributionNot Available
Protein binding92%
Metabolism

Hepatic

SubstrateEnzymesProduct
Haloperidol
4-(4-chlorophenyl)-4-hydroxypiperidineDetails
Haloperidol
Reduced haloperidolDetails
Haloperidol
Haloperidol glucuronideDetails
Haloperidol
Haloperidol 1,2,3,6-tetrahydropyridineDetails
Haloperidol
fluorobenzoylpropionic acidDetails
Haloperidol
4-(4-Chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HPP+)Details
Reduced haloperidol
Not Available
Haloperidol reduced pyridinium ion derivativeDetails
Haloperidol reduced pyridinium ion derivative
Haloperidol pyridinium ion derivativeDetails
Haloperidol 1,2,3,6-tetrahydropyridine
Not Available
Haloperidol pyridinium ion derivativeDetails
Route of eliminationNot Available
Half life3 weeks
ClearanceNot Available
ToxicityLD50=165 mg/kg (rats, oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Haloperidol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineHaloperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineHaloperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Haloperidol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Haloperidol can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Haloperidol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Haloperidol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Haloperidol can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Haloperidol.Investigational
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Haloperidol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Haloperidol.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Haloperidol.Approved
adipiplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Haloperidol.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Haloperidol.Approved
AlbendazoleThe serum concentration of Haloperidol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Haloperidol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Haloperidol can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Haloperidol can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Haloperidol.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Haloperidol.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Haloperidol.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Haloperidol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Haloperidol.Approved, Investigational
Aminohippuric acidThe serum concentration of Haloperidol can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Haloperidol.Approved, Withdrawn
AmiodaroneHaloperidol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Haloperidol.Approved
AmlodipineThe serum concentration of Haloperidol can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Haloperidol.Approved
AmperozideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Haloperidol.Approved, Illicit
AmprenavirThe serum concentration of Haloperidol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Haloperidol can be increased when it is combined with Amsacrine.Approved
AnagrelideHaloperidol may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Haloperidol.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Haloperidol.Approved
ApomorphineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Apomorphine.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Haloperidol.Approved, Investigational
AprepitantThe serum concentration of Haloperidol can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Haloperidol.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
ArmodafinilThe metabolism of Haloperidol can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideHaloperidol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherHaloperidol may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Articaine.Approved
AsenapineHaloperidol may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Haloperidol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Haloperidol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Haloperidol can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Haloperidol.Approved
AtorvastatinThe serum concentration of Haloperidol can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Haloperidol.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Azaperone.Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.Withdrawn
AzelastineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Haloperidol.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Haloperidol.Approved
BaclofenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Baclofen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Haloperidol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.Illicit
BedaquilineHaloperidol may increase the QTc-prolonging activities of Bedaquiline.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Haloperidol.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Haloperidol.Approved
BenzocaineThe serum concentration of Haloperidol can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.Approved
BenzphetamineHaloperidol may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Haloperidol.Approved
BepridilThe serum concentration of Haloperidol can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Haloperidol.Approved, Vet Approved
BetaxololThe metabolism of Haloperidol can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Haloperidol.Investigational
BexaroteneThe serum concentration of Haloperidol can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Haloperidol can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Haloperidol.Approved
BoceprevirThe metabolism of Haloperidol can be decreased when combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
BosentanThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Haloperidol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.Approved
BromocriptineThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Haloperidol.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brotizolam.Approved, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Haloperidol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Haloperidol.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Haloperidol.Approved, Investigational
BuprenorphineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Haloperidol can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Haloperidol.Approved
BuspironeThe serum concentration of Haloperidol can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Haloperidol.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Haloperidol.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.Approved
CandesartanThe serum concentration of Haloperidol can be increased when it is combined with Candesartan.Approved
CapecitabineThe metabolism of Haloperidol can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Haloperidol can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Haloperidol can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Haloperidol.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Haloperidol.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Haloperidol.Approved, Vet Approved, Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Haloperidol.Approved
CarvedilolThe serum concentration of Haloperidol can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Haloperidol can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Haloperidol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Haloperidol.Approved, Vet Approved
CeritinibThe serum concentration of Haloperidol can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Haloperidol.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Haloperidol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Haloperidol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Haloperidol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloroprocaine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Haloperidol.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Haloperidol.Approved
ChlorphentermineHaloperidol may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
ChlorpropamideThe serum concentration of Haloperidol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Haloperidol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Haloperidol.Approved
CholecalciferolThe metabolism of Haloperidol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Haloperidol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Haloperidol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Haloperidol can be increased when it is combined with Cilazapril.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Haloperidol.Approved
CimetidineThe serum concentration of Haloperidol can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Haloperidol can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Haloperidol.Approved
CiprofloxacinHaloperidol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideHaloperidol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Haloperidol.Approved
CitalopramHaloperidol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinHaloperidol may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Haloperidol can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Haloperidol.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Haloperidol.Approved, Illicit
ClofazimineThe serum concentration of Haloperidol can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Haloperidol.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Haloperidol.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Haloperidol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Haloperidol.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Haloperidol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Haloperidol.Approved
CobicistatThe serum concentration of Haloperidol can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Haloperidol.Approved
CocaineThe metabolism of Haloperidol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Haloperidol.Approved
ColforsinThe serum concentration of Haloperidol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Haloperidol can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Haloperidol.Approved
CrizotinibHaloperidol may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Haloperidol.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.Approved
CyclophosphamideThe serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Haloperidol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Haloperidol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Haloperidol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol.Approved
DabrafenibThe serum concentration of Haloperidol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Haloperidol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Haloperidol can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Haloperidol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Haloperidol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Haloperidol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Haloperidol can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Haloperidol.Approved
DasatinibThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Haloperidol can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Haloperidol.Approved
DeferasiroxThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Haloperidol.Approved
DelavirdineThe metabolism of Haloperidol can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Haloperidol is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Haloperidol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Haloperidol.Approved
DesloratadineThe serum concentration of Haloperidol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.Approved
DetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Haloperidol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Haloperidol.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Haloperidol.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Haloperidol.Approved, Illicit
DextromethorphanThe serum concentration of Haloperidol can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Haloperidol.Approved, Illicit, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.Approved, Vet Approved
DiethylpropionHaloperidol may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Haloperidol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Difenoxin.Approved, Illicit
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Haloperidol.Approved
DigoxinThe serum concentration of Haloperidol can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.Approved, Illicit
DihydroergotamineThe metabolism of Haloperidol can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Haloperidol.Illicit
DiltiazemThe metabolism of Haloperidol can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Haloperidol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Haloperidol can be increased when it is combined with Dipyridamole.Approved
DisopyramideHaloperidol may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Haloperidol.Approved, Investigational
DofetilideHaloperidol may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronHaloperidol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneHaloperidol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Haloperidol.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Haloperidol.Approved
DoramectinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Doramectin.Vet Approved
DoxazosinThe serum concentration of Haloperidol can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Haloperidol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.Approved, Investigational
DoxorubicinThe serum concentration of Haloperidol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Haloperidol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Haloperidol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Illicit
DronedaroneHaloperidol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Drotebanol.Experimental, Illicit
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Haloperidol.Approved
DuloxetineThe metabolism of Haloperidol can be decreased when combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Haloperidol.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.Approved
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Haloperidol.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Haloperidol.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Haloperidol is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Haloperidol.Approved
EfavirenzThe serum concentration of Haloperidol can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Haloperidol can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Haloperidol.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Haloperidol.Approved
EnalaprilThe serum concentration of Haloperidol can be increased when it is combined with Enalapril.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Haloperidol.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Haloperidol.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Haloperidol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Haloperidol.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Haloperidol.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.Approved
ErgonovineThe serum concentration of Haloperidol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Haloperidol can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Haloperidol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
EscitalopramHaloperidol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Haloperidol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Haloperidol.Investigational
EsomeprazoleThe metabolism of Haloperidol can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Haloperidol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Haloperidol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Haloperidol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Haloperidol can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.Approved, Investigational
EthanolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Haloperidol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Haloperidol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Haloperidol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etizolam.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Haloperidol.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Haloperidol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etoperidone.Approved
EtoposideThe serum concentration of Haloperidol can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Haloperidol can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Haloperidol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Haloperidol.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Haloperidol.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Haloperidol.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Haloperidol.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Haloperidol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Haloperidol.Approved
FelodipineThe serum concentration of Haloperidol can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Haloperidol.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.Approved
FentanylThe serum concentration of Haloperidol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Haloperidol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Haloperidol.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
FlecainideHaloperidol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Haloperidol.Approved, Withdrawn
FloxuridineThe metabolism of Haloperidol can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Haloperidol can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Haloperidol.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flunitrazepam.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Haloperidol.Vet Approved
FluorouracilThe metabolism of Haloperidol can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
FlupentixolHaloperidol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Haloperidol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Haloperidol can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Haloperidol.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Haloperidol.Approved
FluvoxamineThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
FosamprenavirThe metabolism of Haloperidol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Haloperidol.Approved
FosphenytoinThe metabolism of Haloperidol can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Haloperidol.Approved, Investigational
Fusidic AcidThe serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Haloperidol is combined with gabapentin enacarbil.Approved
Gadobenic acidHaloperidol may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Haloperidol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Haloperidol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Haloperidol.Approved
GemfibrozilThe metabolism of Haloperidol can be decreased when combined with Gemfibrozil.Approved
GemifloxacinHaloperidol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Haloperidol can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Haloperidol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Haloperidol can be increased when it is combined with Glycerol.Experimental
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.Approved
GlycopyrroniumThe serum concentration of Haloperidol can be decreased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Haloperidol.Approved
Gramicidin DThe serum concentration of Haloperidol can be increased when it is combined with Gramicidin D.Approved
GranisetronHaloperidol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Haloperidol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Haloperidol.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Haloperidol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Haloperidol.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Haloperidol.Approved
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Haloperidol.Investigational
HydrocodoneHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Haloperidol.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Haloperidol.Approved, Illicit
Hydroxyamphetamine hydrobromideHaloperidol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Haloperidol.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Haloperidol.Withdrawn
IbutilideHaloperidol may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Haloperidol.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Haloperidol.Approved
IdelalisibThe serum concentration of Haloperidol can be increased when it is combined with Idelalisib.Approved
IloperidoneHaloperidol may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Haloperidol can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Haloperidol.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Haloperidol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Haloperidol.Approved
IndinavirThe metabolism of Haloperidol can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Haloperidol.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.Approved
IrbesartanThe metabolism of Haloperidol can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Haloperidol.Approved, Investigational
IsavuconazoniumThe metabolism of Haloperidol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Haloperidol.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
IsoniazidThe metabolism of Haloperidol can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Haloperidol.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Haloperidol.Approved
ItraconazoleThe metabolism of Haloperidol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Haloperidol.Approved
IvacaftorThe serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Haloperidol.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Haloperidol.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Haloperidol.Experimental
KetamineThe serum concentration of Haloperidol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Haloperidol.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Haloperidol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.Approved
LabetalolThe metabolism of Labetalol can be decreased when combined with Haloperidol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Haloperidol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Haloperidol.Approved, Investigational
LansoprazoleThe serum concentration of Haloperidol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Haloperidol.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Haloperidol.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Haloperidol.Approved
LenvatinibHaloperidol may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Haloperidol.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Levodopa.Approved
LevofloxacinHaloperidol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Haloperidol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Haloperidol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Haloperidol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Haloperidol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.Approved, Investigational
LiothyronineThe serum concentration of Haloperidol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Haloperidol can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Haloperidol can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Haloperidol.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Haloperidol.Approved
LithiumLithium may increase the neurotoxic activities of Haloperidol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Haloperidol can be increased when it is combined with Lomitapide.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Haloperidol.Approved
LoperamideThe serum concentration of Haloperidol can be increased when it is combined with Loperamide.Approved
LopinavirHaloperidol may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Haloperidol can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Haloperidol.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.Approved
LosartanThe serum concentration of Haloperidol can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Haloperidol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Haloperidol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Haloperidol.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Haloperidol is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Haloperidol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Haloperidol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineHaloperidol may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Haloperidol.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Haloperidol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Haloperidol.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Haloperidol.Approved
MebendazoleThe serum concentration of Haloperidol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meclizine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.Approved, Vet Approved
MedetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Medetomidine.Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Haloperidol.Approved
Megestrol acetateThe serum concentration of Haloperidol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Haloperidol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Melperone.Approved
MephedroneHaloperidol may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineHaloperidol may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Haloperidol.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Haloperidol can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineHaloperidol may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Haloperidol.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Haloperidol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Haloperidol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Haloperidol.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Haloperidol.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Haloperidol.Approved
MethotrimeprazineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Haloperidol.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Haloperidol.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Haloperidol.Approved, Illicit, Withdrawn
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Haloperidol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Haloperidol.Approved
MetyrosineHaloperidol may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Haloperidol can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Haloperidol.Approved
MibefradilThe serum concentration of Haloperidol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Haloperidol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Haloperidol can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Haloperidol.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Haloperidol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Haloperidol.Approved
MirtazapineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Haloperidol can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Haloperidol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Haloperidol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Haloperidol.Investigational
MMDAHaloperidol may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Haloperidol.Approved
ModafinilThe serum concentration of Haloperidol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Haloperidol.Approved
MolindoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Haloperidol.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Haloperidol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Haloperidol.Investigational
NafcillinThe serum concentration of Haloperidol can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Haloperidol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Haloperidol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Haloperidol.Approved, Vet Approved
NaltrexoneThe serum concentration of Haloperidol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.Approved, Investigational
NaringeninThe serum concentration of Haloperidol can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Haloperidol.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Haloperidol.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.Approved, Investigational
NefazodoneThe metabolism of Haloperidol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Haloperidol can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Haloperidol can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Haloperidol.Approved
NetupitantThe serum concentration of Haloperidol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Haloperidol can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Haloperidol can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Haloperidol.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Haloperidol.Approved
NifedipineThe serum concentration of Haloperidol can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.Approved
NilotinibHaloperidol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Haloperidol.Approved
NisoldipineThe serum concentration of Haloperidol can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Haloperidol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Haloperidol can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Haloperidol.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Haloperidol.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Haloperidol.Approved
NorethisteroneThe serum concentration of Haloperidol can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Haloperidol.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Haloperidol.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
OfloxacinHaloperidol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
OlaparibThe metabolism of Haloperidol can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Haloperidol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Haloperidol.Approved
OmeprazoleThe serum concentration of Haloperidol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronHaloperidol may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Opium.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Haloperidol.Vet Approved
OrphenadrineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Haloperidol can be increased when it is combined with Osimertinib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.Approved
OxazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxybuprocaine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Haloperidol.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Haloperidol.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
P-NitrophenolThe serum concentration of Haloperidol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Haloperidol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.Approved
PaliperidoneHaloperidol may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Haloperidol can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Haloperidol.Approved, Investigational
PanobinostatThe serum concentration of Haloperidol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.Approved
ParaldehydeHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Haloperidol.Approved
ParoxetineThe metabolism of Haloperidol can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Haloperidol.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Haloperidol.Approved
Peginterferon alfa-2bThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineHaloperidol may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Haloperidol can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
PerazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perazine.Investigational
PerflutrenHaloperidol may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Haloperidol.Approved
PerindoprilThe serum concentration of Haloperidol can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Haloperidol.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Haloperidol.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Haloperidol.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Haloperidol.Approved, Withdrawn
PhenobarbitalThe metabolism of Haloperidol can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Phenoxyethanol.Approved
PhentermineHaloperidol may decrease the stimulatory activities of Phentermine.Approved, Illicit
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Haloperidol.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Haloperidol.Approved, Vet Approved
PhenytoinThe metabolism of Haloperidol can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.Approved, Investigational
PimozideHaloperidol may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Haloperidol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Haloperidol.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Haloperidol.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.Investigational
PiribedilThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Piritramide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Haloperidol.Approved
PizotifenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Haloperidol can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Haloperidol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Haloperidol.Approved
PosaconazoleThe metabolism of Haloperidol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleHaloperidol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Haloperidol.Approved
PrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Haloperidol can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Haloperidol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Haloperidol.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Haloperidol.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prilocaine.Approved
PrimaquineHaloperidol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Haloperidol can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Haloperidol can be increased when it is combined with Probenecid.Approved
ProcainamideHaloperidol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Haloperidol.Approved, Vet Approved
ProgesteroneThe serum concentration of Haloperidol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Haloperidol.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Haloperidol.Approved
PropafenoneThe serum concentration of Haloperidol can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Haloperidol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Haloperidol.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Haloperidol.Approved
PSD502The risk or severity of adverse effects can be increased when Haloperidol is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Haloperidol.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Haloperidol.Investigational
PyrimethamineThe metabolism of Haloperidol can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Haloperidol can be increased when it is combined with Quercetin.Experimental
QuetiapineHaloperidol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Haloperidol can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.Approved
QuinidineHaloperidol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineHaloperidol may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Haloperidol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Haloperidol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.Approved
ReboxetineThe serum concentration of Haloperidol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Haloperidol can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Haloperidol.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Haloperidol.Investigational
ReserpineThe serum concentration of Haloperidol can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.Experimental, Investigational
RifabutinThe metabolism of Haloperidol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Haloperidol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Haloperidol can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Haloperidol.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Haloperidol.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ritanserin.Investigational
RitobegronHaloperidol may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Haloperidol can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Haloperidol.Investigational, Withdrawn
RolapitantThe serum concentration of Haloperidol can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Haloperidol.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Romifidine.Vet Approved
RopiniroleHaloperidol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Haloperidol.Approved
RotigotineHaloperidol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Haloperidol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Haloperidol is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Haloperidol is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Haloperidol.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Haloperidol.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.Approved
SaquinavirHaloperidol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Haloperidol can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Haloperidol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Haloperidol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Haloperidol.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Haloperidol.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Haloperidol.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Haloperidol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
SildenafilThe metabolism of Haloperidol can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Haloperidol.Approved
SiltuximabThe serum concentration of Haloperidol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Haloperidol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Haloperidol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Haloperidol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Haloperidol.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Haloperidol.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Haloperidol.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Haloperidol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
SotalolHaloperidol may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Haloperidol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Haloperidol.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Haloperidol.Experimental
SpironolactoneThe serum concentration of Haloperidol can be increased when it is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Haloperidol.Investigational
St. John's WortThe serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Haloperidol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Haloperidol can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Haloperidol can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Haloperidol can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Haloperidol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Haloperidol.Approved
SulfinpyrazoneThe serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.Approved
SulpirideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Haloperidol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.Approved, Withdrawn
SuvorexantHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Haloperidol can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Haloperidol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Haloperidol.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Haloperidol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Haloperidol.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Haloperidol.Investigational, Withdrawn
TelaprevirThe metabolism of Haloperidol can be decreased when combined with Telaprevir.Approved
TelavancinHaloperidol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinHaloperidol may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe serum concentration of Haloperidol can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.Approved
TenofovirThe metabolism of Haloperidol can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Haloperidol.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Haloperidol.Vet Approved
TerazosinThe serum concentration of Haloperidol can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Haloperidol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Haloperidol.Approved
TerfenadineThe serum concentration of Haloperidol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Haloperidol.Approved
TesmilifeneThe serum concentration of Haloperidol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Haloperidol can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.Approved
TetracaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrodotoxin.Investigational
ThalidomideHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Haloperidol can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Haloperidol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiapride.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Haloperidol.Approved
TiclopidineThe metabolism of Haloperidol can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Haloperidol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Haloperidol.Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Haloperidol.Approved
TipranavirThe metabolism of Haloperidol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Haloperidol.Approved
TocilizumabThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Haloperidol can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Haloperidol.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Haloperidol.Approved
TopiramateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Haloperidol.Approved, Investigational
ToremifeneHaloperidol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Haloperidol.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Haloperidol can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Haloperidol.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triazolam.Approved
TrifluoperazineThe serum concentration of Haloperidol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Haloperidol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Haloperidol.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Haloperidol.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Haloperidol.Approved
TroleandomycinThe serum concentration of Haloperidol can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Haloperidol is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Haloperidol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Haloperidol.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Haloperidol.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Haloperidol.Approved, Investigational
ValsartanThe metabolism of Haloperidol can be decreased when combined with Valsartan.Approved, Investigational
VandetanibHaloperidol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Haloperidol.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Haloperidol.Approved
VemurafenibThe serum concentration of Haloperidol can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Haloperidol.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Haloperidol.Approved
VerapamilThe metabolism of Haloperidol can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Haloperidol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Haloperidol.Approved
VinblastineThe serum concentration of Haloperidol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Haloperidol.Approved, Investigational
VincristineThe serum concentration of Haloperidol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Haloperidol.Approved
VoriconazoleThe metabolism of Haloperidol can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Haloperidol.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Haloperidol.Approved
XylazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Haloperidol.Approved, Vet Approved
ZafirlukastThe metabolism of Haloperidol can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Haloperidol.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zaleplon.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Haloperidol.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Haloperidol.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Haloperidol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Haloperidol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneHaloperidol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol.Approved, Investigational
ZolpidemHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zotepine.Approved
ZuclopenthixolHaloperidol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.
References
Synthesis Reference

DrugSyn.org

US3438991
General References
  1. Niemegeers CJ, Laduron PM: Pharmacology and biochemistry of haloperidol. Proc R Soc Med. 1976;69 suppl 1:3-8. [PubMed:14331 ]
External Links
ATC CodesN05AD01
AHFS Codes
  • 28:16.08.08
PDB EntriesNot Available
FDA labelDownload (169 KB)
MSDSDownload (73.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9465
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8137
Renal organic cation transporterInhibitor0.6058
CYP450 2C9 substrateNon-substrate0.8355
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5796
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9207
CYP450 2D6 inhibitorInhibitor0.9197
CYP450 2C19 inhibitorNon-inhibitor0.9248
CYP450 3A4 inhibitorInhibitor0.6899
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8769
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4367 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.7474
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil pharmaceutical
  • Ortho mcneil pharmaceutical inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Roxane laboratories inc
  • Royce laboratories inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Alpharma uspd inc
  • Morton grove pharmaceuticals inc
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Ortho mcneil janssen pharmaceuticals inc
  • Abraxis pharmaceutical products
  • Akorn strides llc
  • Gland pharma ltd
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Solopak laboratories inc
  • Actavis mid atlantic llc
Packagers
Dosage forms
FormRouteStrength
LiquidOral2 mg
TabletOral.5 mg
TabletOral1 mg
TabletOral10 mg
TabletOral2 mg
TabletOral5 mg
InjectionIntramuscular5 mg/1
InjectionIntramuscular5 mg/mL
Injection, solutionIntramuscular5 mg/mL
Injection, solutionOral5 mg/mL
SolutionOral2 mg/mL
Solution, concentrateOral2 mg/mL
TabletOral.5 mg/1
TabletOral1 mg/1
TabletOral10 mg/1
TabletOral2 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
InjectionIntramuscular100 mg/mL
InjectionIntramuscular50 mg/mL
LiquidIntramuscular5 mg
SolutionIntramuscular5 mg
LiquidIntramuscular100 mg
LiquidIntramuscular50 mg
TabletOral0.5 mg
SolutionOral2 mg
SolutionIntramuscular100 mg
SolutionIntramuscular50 mg
TabletOral20 mg
Prices
Unit descriptionCostUnit
Haloperidol Decanoate 100 mg/ml Solution 5ml Vial257.14USD vial
Haldol decanoate 100 ampul107.77USD ml
Haldol decanoate 50 ampul56.53USD ml
Haloperidol dec 100 mg/ml vial29.85USD ml
Haloperidol powder21.42USD g
Haloperidol dec 50 mg/ml vial17.71USD ml
Haloperidol La 100 mg/ml15.42USD ml
Haldol 5 mg/ml ampul13.4USD ml
Haloperidol La 50 mg/ml7.71USD ml
Haloperidol 5 mg/ml4.73USD ml
Haloperidol lac 5 mg/ml vial3.54USD ml
Haloperidol 20 mg tablet2.81USD tablet
Haloperidol 10 mg tablet1.46USD tablet
Haloperidol 5 mg tablet0.8USD tablet
Novo-Peridol 20 mg Tablet0.66USD tablet
Haloperidol 2 mg tablet0.49USD tablet
Haloperidol lac 2 mg/ml conc0.45USD ml
Haloperidol 1 mg tablet0.36USD tablet
Haloperidol 0.5 mg tablet0.25USD tablet
Pernox scrub cleanser0.18USD g
Apo-Haloperidol 5 mg Tablet0.16USD tablet
Novo-Peridol 5 mg Tablet0.16USD tablet
Apo-Haloperidol 10 mg Tablet0.14USD tablet
Novo-Peridol 10 mg Tablet0.14USD tablet
Apo-Haloperidol 2 mg Tablet0.11USD tablet
Novo-Peridol 2 mg Tablet0.11USD tablet
Apo-Haloperidol 1 mg Tablet0.06USD tablet
Novo-Peridol 1 mg Tablet0.06USD tablet
Apo-Haloperidol 0.5 mg Tablet0.04USD tablet
Novo-Peridol 0.5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.5 °CPhysProp
water solubility14 mg/L (at 25 °C)MERCK INDEX (1996)
logP4.30EL TAYAR,N ET AL. (1985)
logS-4.43ADME Research, USCD
pKa8.66EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00446 mg/mLALOGPS
logP3.7ALOGPS
logP3.66ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.96ChemAxon
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity102.59 m3·mol-1ChemAxon
Polarizability39.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0079-3290000000-cc6a990404ba7b9452a8View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylbutylamine
  • Butyrophenone
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Gamma-aminoketone
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. [PubMed:15894081 ]
  2. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, Bolognani F, Lauriello J, Perrone-Bizzozero N, Galloway MP: Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006 Apr;31(4):751-6. [PubMed:16132064 ]
  3. Ishiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, Sasaki T, Naganawa M, Chihara K, Okubo Y, Ishii K: A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med. 2006 Oct;20(8):569-73. [PubMed:17134027 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  6. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  7. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  8. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S: Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem. 2006 Mar 17;281(11):7129-35. Epub 2006 Jan 10. [PubMed:16407246 ]
  2. Zhuravliova E, Barbakadze T, Natsvlishvili N, Mikeladze DG: Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity. Neurochem Int. 2007 Jun;50(7-8):976-82. Epub 2006 Nov 7. [PubMed:17092607 ]
  3. Gu WH, Yang S, Shi WX, Zhen XC, Jin GZ: Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine. Acta Pharmacol Sin. 2007 Jul;28(7):953-8. [PubMed:17588330 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Steinmetz RD, Fava E, Nicotera P, Steinhilber D: A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands. J Neurosci Methods. 2002 Jan 15;113(1):99-110. [PubMed:11741727 ]
  6. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E: NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci. 2000 Dec 1;20(23):8831-7. [PubMed:11102491 ]
  7. Gallagher MJ, Huang H, Lynch DR: Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem. 1998 May;70(5):2120-8. [PubMed:9572299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inverse agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J: Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci. 2009 Aug;63(4):529-37. doi: 10.1111/j.1440-1819.2009.01982.x. Epub 2009 May 22. [PubMed:19496999 ]
  3. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. doi: 10.1016/j.ejphar.2008.09.008. Epub 2008 Sep 20. [PubMed:18831971 ]
  4. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology. 2005 Dec;30(12):2283-9. [PubMed:16123775 ]
  5. Malmberg, Mikaels, Mohell N: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding. J Pharmacol Exp Ther. 1998 Apr;285(1):119-26. [PubMed:9536001 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Tateishi T, Watanabe M, Kumai T, Tanaka M, Moriya H, Yamaguchi S, Satoh T, Kobayashi S: CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20. [PubMed:11133003 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9. [PubMed:12584149 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-e2 9-reductase activity
Specific Function:
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alp...
Gene Name:
CBR1
Uniprot ID:
P16152
Molecular Weight:
30374.73 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  3. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46